M&G Plc Purchases 57,709 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

M&G Plc grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 59.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 154,717 shares of the biopharmaceutical company’s stock after purchasing an additional 57,709 shares during the quarter. M&G Plc’s holdings in Gilead Sciences were worth $10,675,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in GILD. International Assets Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $1,649,000. Cerity Partners LLC lifted its stake in shares of Gilead Sciences by 102.4% in the 4th quarter. Cerity Partners LLC now owns 146,740 shares of the biopharmaceutical company’s stock valued at $11,888,000 after purchasing an additional 74,249 shares during the period. Sapient Capital LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $324,000. Valeo Financial Advisors LLC lifted its stake in shares of Gilead Sciences by 7.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 7,363 shares of the biopharmaceutical company’s stock valued at $596,000 after purchasing an additional 491 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Gilead Sciences during the 4th quarter worth $49,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $73.98 on Wednesday. The firm has a market cap of $92.17 billion, a price-to-earnings ratio of 205.50, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The stock’s 50-day moving average is $70.20 and its 200-day moving average is $70.30. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.16%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analyst Ratings Changes

Several analysts recently commented on the company. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research note on Wednesday, April 24th. Royal Bank of Canada raised their price objective on Gilead Sciences from $71.00 to $72.00 and gave the stock a “sector perform” rating in a research note on Friday, August 9th. TD Cowen dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $81.88.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.